Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Neutropenia Therapy
New neutropenia therapy study findings recently were published by researchers at Southampton General Hospital, Department of Medical Oncology
April 16th, 2007
A report, "ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors," is newly published data in Annals of Oncology. "We investigated whether administration of full-dose ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy without growth factors, and irrespective of the granulocyte count, caused treatment delays or increased the number of infective episodes, in patients with Hodgkin's lymphoma (HL). Thirty-eight patients with confirmed predominantly early-stage HL were treated with ABVD outside clinical trial protocols over a 5-year period on an outpatient basis. Ninety-five per cent of patients completed their scheduled ABVD...
Source: Hematology Week (2007-04-16)
|
